Hansom Pharmaceuticals: Subsidiary company signs agreement with Glenmark Specialty S.A. for the purchase of Amezitinib.
Johnson Pharmaceuticals announced on the Hong Kong Stock Exchange that on December 16, 2025, its wholly-owned subsidiary Jiangsu Haosen Pharmaceutical Group Co., Ltd. has entered into an exclusive licensing, cooperation, and distribution agreement with Glenmark Specialty S.A. for Ameitinib. Ameitinib is a third-generation tyrosine kinase inhibitor used for the treatment of non-small cell lung cancer. According to the licensing agreement, the licensor will grant the licensee exclusive permission to develop and commercialize Ameitinib in the authorized area.
Latest

